NCT03302884

Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Institut Paoli-Calmettes · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Prospective multicentre assay to assess ctDNA value for ovarian cancer monitoring and disease recurrence after front-line treatment.

Detailed description

The main objective is to explore the capacity of ctDNA to be an early marker of ovarian carcinoma recurrence after front-line treatments, i.e. to show significant modifications before clinical diagnosis of disease relapse. Prospective multicentre open-label study During visits in the frame of management of the disease, blood samples will be collected at diagnosis, after each cycle of eventual neoadjuvant chemotherapy, every 6 months during the following 2 years, and every year during the remainin time of follow-up. Tumor samples will be collected at surgery or through a biopsy. Patients will then have a standard care follow-up for a period of 5 years.

Conditions

• Ovarian Carcinoma

Interventions

Type	Name	Description
OTHER	biological sampling	Tumor and blood samples

Timeline

• Start date: 2018-10-10
• Primary completion: 2023-10-30
• Completion: 2023-10-30
• First posted: 2017-10-05
• Last updated: 2019-09-26

Locations

3 sites across 1 country: France